Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
-
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
-
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
-
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
-
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
-
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of NF1 Associated Plexiform Neurofibromas
-
Pasithea Therapeutics (Nasdaq: KTTA) will present to Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 25, 2026, 4:00 PM ET
-
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
-
Extends cash runway through at least the first half of 2028Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle...
-
Extends cash runway through at least the first half of 2028Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron...